Lignin-Graft-Plga Drug-Delivery System Improves Efficacy of MEK1/2 Inhibitors in Triple-Negative Breast Cancer Cell Line

• DOI: 10.2217/nnm-2020-0010
• Publication Date: 2020-04-02T12:05:31Z
• Authors: C Ethan Byrne; Carlos E Astete; Manibarathi Vaith...; Adam T Melvin; Mahsa Moradipour; Stephen E Rankin; Barbara L Knutson; Cristina M Sabliov; Elizabeth C Martin
• Keywords: Triple-negative breast cancer; PLGA

Aim: Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared PLGA NPs. Results: Loaded NPs less than half size NPs, had slower release improved when vitro. We demonstrated that reversed epithelial-to-mesenchymal transition TNBC. Conclusion: Our findings indicate superior delivering cells